Panelists discuss how antifibrotic therapies for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) slow disease progression despite challenges with cost, tolerability, and ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced new study results showing that use of the Envisia® Genomic Classifier improves physicians’ ability to ...

Please provide your email address to receive an email when new articles are posted on . Patients with idiopathic pulmonary fibrosis appear to have higher cumulative incidences of exertional and ...

Even after diagnosis, idiopathic pulmonary fibrosis patients often delay treatment because they don’t feel "sick enough." Boehringer Ingelheim wants to change that with a global campaign touting the ...

Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...

The location of the tumors was in the lower lobe in 9 patients at the initial surgery and in 8 patients at the second surgery. Of the 13 patients, 8 patients (61.5%) underwent lobectomy, 2 patients ...

Idiopathic pulmonary fibrosis (IPF) is a lung disease in which lung tissue becomes progressively scarred and stiff. This makes it increasingly difficult to breathe. There’s currently no cure for IPF, ...

The Oscar-winning actress shares what she learned as a caregiver, and what doctors can do to give patients with IPF more hope ...

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease, with only about 10 to 60 cases per 100,000 people in the United States. So you’ll likely find that many people have never heard of IPF. The ...